Capricor Therapeutics (NASDAQ:CAPR) Earns Overweight Rating from Analysts at Piper Sandler

Piper Sandler started coverage on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research note issued to investors on Monday, Marketbeat.com reports. The brokerage issued an overweight rating and a $35.00 target price on the biotechnology company’s stock.

Several other equities analysts have also weighed in on the stock. Maxim Group raised their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $8.00 price target on shares of Capricor Therapeutics in a research note on Friday, September 20th. Finally, Oppenheimer reiterated an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $24.67.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $21.21 on Monday. Capricor Therapeutics has a 52 week low of $2.68 and a 52 week high of $23.40. The company’s 50-day moving average price is $10.40 and its two-hundred day moving average price is $6.92.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The firm had revenue of $3.97 million during the quarter, compared to analyst estimates of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. Equities research analysts forecast that Capricor Therapeutics will post -1.17 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the stock in a transaction dated Friday, September 20th. The stock was bought at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the purchase, the insider now directly owns 7,090,351 shares in the company, valued at $38,004,281.36. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 12.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets acquired a new position in shares of Capricor Therapeutics in the 1st quarter valued at approximately $40,000. SG Americas Securities LLC acquired a new position in shares of Capricor Therapeutics in the 3rd quarter valued at approximately $133,000. Main Street Financial Solutions LLC grew its position in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the period. Rhumbline Advisers acquired a new position in shares of Capricor Therapeutics in the 2nd quarter valued at approximately $147,000. Finally, Bank of New York Mellon Corp grew its position in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.